Class 4 Medicines Defect Notification: Brilique 90mg Tablets, El(25)a/18
Brilique 90mg Tablets Recall Summary Brilique 90mg tablets distributed in the United Kingdom have a spelling error on the carton where the active ingredient is printed as "Tricagelor" instead of the correct spelling "Ticagrelor." This defect was identified by G Pharma Ltd and reported to the MHRA. The tablets themselves are not affected, only the labeling on the imported cartons is incorrect.
- Recalling firm
- Brilique 90mg Tablets
- Reason
- G Pharma Ltd have informed the MHRA that there is an error in the spelling of the active ingredient included on the imported carton. The spelling should be ‘Ticagrelor’ but has been printed as ‘Tricagelor’ under the brand name and in the content statement.
- Classification
- Class III
- Category
- drug recall
- Country
- United Kingdom
- Agency
- UK Medicines and Healthcare products Regulatory Agency
- Recall date
- 2025-04-24
- Status
- Ongoing
- Distribution
- United Kingdom
Official recall notice from UK Medicines and Healthcare products Regulatory Agency
Recall details on Nibble Recalls: https://trynibble.app/recalls/272c707a-bd6d-4ab7-996e-cf79480b346d